Vy H. Nguyen

Vy H. Nguyen

Auto-generated profile, based on publicly available information

Vy H. Nguyen

Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Journal of Viral Hepatitis
Verified
Journal Article
Open access
BHBethany Holt
Bethany Holt
JMJhaki Mendoza
Jhaki Mendoza
HNHoang Nguyen
Hoang Nguyen
DDDuong Doan
Duong Doan
VNVy H Nguyen
Vy H Nguyen
DDDavid Duong
David Duong
In Vietnam and the Philippines, viral hepatitis is the leading cause of cirrhosis and liver cancer. This study aims to understand the barriers and enablers of people receiving care for hepatitis B and C to support both countries' efforts to eliminate viral hepatitis as a public health threat by 2030. Retrospective, semi‐structured interviews were conducted with a purposive, quota‐based sample of 63 people living with hepatitis B or C in one province of Vietnam and one region of the Philippines. A rapid deductive approach to thematic analysis produced key findings among the three phases of care: (1) pre‐awareness and testing, (2) linkage and treatment initiation and (3) ongoing treatment and recovery. The research found that participants followed five typical journeys, from a variety of entry points. Barriers during the pre‐awareness and testing phase included limited awareness about hepatitis and its management, stigma and psychological impacts. Enablers included being familiar with the health system and/or patients benefiting from social connections within the health systems. During the linkage and treatment initiation phase, barriers included difficult physical access, complex navigation and inadequate counselling. In this phase, family support emerged as a critical enabler. During the ongoing treatment and recovery phase, the cost of care and socially and culturally informed perceptions of the disease and medication use were both barriers and enablers. Exploring peoples' journeys with hepatitis B and C in Vietnam and the Philippines revealed many similarities despite the different cultural and health system contexts. Insights from this study may help generate a contextualized, people‐centred evidence base to inform the design and improvement of primary care services for hepatitis in both research sites.

16 December 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JCJonggi Choi
Jonggi Choi
VNVy H. Nguyen
Vy H. Nguyen
EPEric Przybyszewski
Eric Przybyszewski
JSJiunn Song
Jiunn Song
ACAllison Carroll
Allison Carroll
RCRaymond T. Chung
Raymond T. Chung
INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely prescribed for type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects. This study investigated their association with hepatocellular carcinoma (HCC) risk compared with other antidiabetic medications. METHODS: We conducted a retrospective cohort study using the electronic health records from Mass General Brigham (Boston, USA) and Asan Medical Center (Seoul, Korea) from 2013 to 2024. Adults with T2DM newly initiating SGLT2i, dipeptidyl peptidase-4 inhibitor (DPP4i), glucagon-like peptide-1 receptor agonist (GLP-1RA), or sulfonylureas were included. A 6-month landmark analysis was used to minimize early event bias. Inverse probability weighting combined with Fine-Gray competing risk models estimated subdistribution hazard ratios (SHRs) for incident HCC, accounting for transplant and death as competing events. RESULTS: After weighting, data from 6,733 SGLT2i, 4,495 GLP-1RA, 23,229 DPP4i, and 17,034 sulfonylurea initiators were analyzed. Over a median follow-up of 3.9 years (277,155 person-years), 623 HCC cases occurred. SGLT2i use was associated with significantly lower HCC risk vs sulfonylureas (SHR 0.44, 95% confidence interval [CI]: 0.25–0.79) and DPP4i (SHR 0.53, 95% CI: 0.30–0.93). The comparison with GLP-1RA showed comparable risk (SHR 0.87, 95% CI: 0.40–1.91). Subgroup analyses demonstrated consistent protective associations of SGLT2i in patients aged 65 years and younger, men, and those with chronic liver disease. Sensitivity analyses, including 12-month landmark analysis and adjustments for additional confounders, confirmed robustness of findings. DISCUSSION: SGLT2 inhibitor therapy was associated with reduced risk of HCC compared with DPP4 inhibitors and sulfonylureas, supporting their potential chemopreventive role in patients with T2DM.

12 May 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
EAErik Almazan
Erik Almazan
JCJonggi Choi
Jonggi Choi
TKTushar Kamath
Tushar Kamath
VNVy H. Nguyen
Vy H. Nguyen
EPEric Przybyszewski
Eric Przybyszewski
RCRaymond T. Chung
Raymond T. Chung
INTRODUCTION: Randomized clinical trials indicate that glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment improves histologic endpoints in steatotic liver disease, but its effects on long-term clinical outcomes remain uncertain. We examined the association between GLP-1 RA use and hepatic complications in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). METHODS: We conducted a retrospective, new-user cohort study emulating sequential monthly target trials using All of Us Research Program data from 2010 to 2023 to compare GLP-1 RA users with propensity score-matched controls. Eligible participants had MASLD and T2DM. We excluded participants with previous hepatic complications or other chronic liver diseases. The primary outcome was a composite of incident cirrhosis, hepatic decompensation, hepatocellular carcinoma, or liver transplantation. We performed intention-to-treat and per-protocol analyses. RESULTS: A total of 2,110 GLP-1 RA users were matched to 2,110 nonusers. Over a median follow-up of 2.7 years, 187 hepatic complication events occurred: 74 among GLP-1 RA users (13.5 per 1,000 person-years) and 113 among nonusers (21.9 per 1,000 person-years). GLP-1 RA use was associated with a 38% lower risk in the intention-to-treat analysis (hazard ratio, 0.62; 95% confidence interval, 0.46–0.83; P = 0.003) and a 42% lower risk in the per-protocol analysis (hazard ratio, 0.58; 95% confidence interval, 0.42–0.80; P = 0.001). Subgroup analyses by baseline fibrosis-4 and body mass index demonstrated consistent directional trends. Landmark analyses at 6 months were consistent with the primary findings. A negative control outcome, incident fracture, showed no association. DISCUSSION: In a nationwide, diverse cohort of individuals with MASLD and T2DM, GLP-1 RA use was associated with a reduction in hepatic complication events, supporting a potential hepatoprotective effect in real-world clinical practice.

12 December 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
XZXinrong Zhang
Xinrong Zhang
VNVy H Nguyen
Vy H Nguyen
LKLeslie Yeeman Kam
Leslie Yeeman Kam
SBScott D Barnett
Scott D Barnett
LHLinda Henry
Linda Henry
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Background: We investigated the association of metabolic risk factors (MRFs) and statin use with liver and nonliver outcomes in a nationwide cohort of patients with chronic hepatitis B (CHB) in the United States. Methods: We conducted a retrospective cohort study of adult patients with CHB using the MarketScan Databases (January 2007–December 2021). Incidence of liver and nonliver outcomes (cardiovascular disease, chronic kidney disease, and extrahepatic cancer) was analyzed. MRFs included diabetes mellitus (DM), hypertension, hyperlipidemia, and obesity. Results: The study included 52 277 patients with CHB, and 1:1 propensity score matching yielded 16 696 pairs of matched patients with and without MRFs for analysis. When compared with those without MRFs, patients with DM and all 3 other MRFs had the highest adjusted hazard ratio (95% CI) for any liver outcome at 2.08 (1.22–3.52), followed by 12.98 (7.73–21.80) for cardiovascular disease, 9.25 (5.46–15.66) for chronic kidney disease, and 2.01 (1.00–4.04) for extrahepatic cancer. Increased metabolic burden was associated with liver and nonliver outcomes except for comparison between patients without MRFs and those with MRFs but no DM (P > .2 for all liver outcomes). Among lower metabolic burden (≤2 MRFs), statin use was associated with a 15% lower risk of any liver outcomes, 35% reduced risk of HCC, and 15% lower risk of cirrhosis but not among those with higher metabolic burden (≥3 MRFs). Conclusions: Higher metabolic burden was associated with a greater risk for liver and nonliver complications in patients with CHB, with DM having the highest impact among other MRFs. Statin use was associated with a reduced risk of liver outcomes among lower metabolic burden.

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
VNVy H. Nguyen
Vy H. Nguyen
ALAn K. Le
An K. Le
MCMimi Chung
Mimi Chung
TJTiffani Johnson
Tiffani Johnson
BLBrian Levitt
Brian Levitt
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

1 April 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
VNV.H. Nguyen
V.H. Nguyen
ALA. Le
A. Le
MCM. Chung
M. Chung
TJT. Johnson
T. Johnson
BLB. Levitt
B. Levitt
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen